Technology Review writes that gene-editing approaches could be employed to make astronauts better suited to space travel.
Harvard researchers call for a discussion and development of guidelines for 'embryoid' research, NPR reports.
In Science this week: a suite of studies from the Synthetic Yeast genome Project.
The worldwide distribution agreement expands Oxford's existing product and service portfolio, streamlining workflows for current customers, the company said.
The UN Convention on Biodiversity has rejected a moratorium on gene drives, Nature News says.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The President's Council of Advisors on Science and Technology urges the adoption of a biodefense strategy, Tech Review reports.
The company said it would use the funding to continue licensing its DNA design technology in the cell and gene therapy markets.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
In Science this week: effort to reduce E. coli genome, and more.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.